FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC detection and compliance, potentially extending patient survival.
Ault Alliance reported quarterly earnings of 14 cents per share, an increase over losses of $41.24 per share from the same period last year. Quarterly revenue clocked in at $44.93 million this quarter, representing a 55.24% increase over revenue of $28.94 million from the prior year's quarter.
Tesla has increased its 72 month loan rate (APR) in the U.S. from 0.99% to 1.99%, according to Benzinga Pro. The loan rates for 36, 48 and 60 month loan terms are still set at 0.99%.
Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infections, show significant improvement in time to catheter failure and overall treatment success.